Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1

Conditions

Hodgkin Disease 12Lymphoma 11Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Recurrence 6Lymphoma, T-Cell, Cutaneous 6Sezary Syndrome 5Mycosis Fungoides 5Lymphoma, Mantle-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Waldenstrom Macroglobulinemia 4Multiple Myeloma 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Immunoblastic Lymphadenopathy 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Burkitt Lymphoma 3Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1

Interventions

duvelisib 3parsaclisib 1obinutuzumab 1liposomal doxorubicin 1chiauranib 1Taxes 1Rituximab 1Panobinostat 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Everolimus 1Doxorubicin 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Panobinostat × Lymphoid × Clear all
NCT01341834 2018-04-24

Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

National Cancer Centre, Singapore

Phase 1 Unknown
49 enrolled
Head & NeckLymphoid

Nasopharyngeal Carcinoma, Lymphoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡